Breast Cancer and Therapy-Related Cardiovascular Toxicity
- PMID: 38769686
- PMCID: PMC11221208
- DOI: 10.4048/jbc.2024.0085
Breast Cancer and Therapy-Related Cardiovascular Toxicity
Abstract
The global incidence of breast cancer is on the rise, a trend also observed in South Korea. However, thanks to the rapid advancements in anticancer therapies, survival rates are improving. Consequently, post-treatment health and quality of life for breast cancer survivors are emerging as significant concerns, particularly regarding treatment-related cardiotoxicity. In this review, we delve into the cardiovascular complications associated with breast cancer treatment, explore surveillance protocols for early detection and diagnosis of late complications, and discuss protective strategies against cardiotoxicity in breast cancer patients undergoing anticancer therapy, drawing from multiple guidelines.
Keywords: Anthracyclines; Breast Neoplasms; Cardiotoxicity; Echocardiography; Trastuzumab.
© 2024 Korean Breast Cancer Society.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
References
-
- Ferlay JE, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, et al. Global Cancer Observatory: Cancer Today. [Accessed March 31st, 2022]. https://gco.iarc.fr/today .
-
- Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–1075. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
